Patients with cancers of the gullet, stomach and bowel respond well to new anti-HER2 drug

(ECCO-the European CanCer Organisation) An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumor activity in a number of cancers including those of the gullet (esophagus), stomach and bowel.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news